Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment

Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment

Copyright © 2018 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 198(2019) vom: 01. Jan., Seite 31-38
1. Verfasser: Xia, Muye (VerfasserIn)
Weitere Verfasser: Liao, Guichan, Chen, Hongjie, Wu, Yin, Fan, Rong, Zhang, Xiaoyong, Peng, Jie
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Observational Study Research Support, Non-U.S. Gov't CXCL13 Clinical relapse Discontinuation HBsAg loss Nucleos(t)ide analogue Antiviral Agents CXCL13 protein, human mehr... Chemokine CXCL13 Cytokines Hepatitis B Surface Antigens Nucleosides
Online verfügbar Volltext